National Health Act 1953 Declaration under subsection 85(2) (No. PB 37 of 2007) (Cth)
COMMONWEALTH OF AUSTRALIA
National Health Act 1953
PHARMACEUTICAL BENEFITS
DECLARATION UNDER SUBSECTION 85(2)
No. PB 37 of 2007
I, STEPHEN DELLAR, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing and Delegate of the Minister for Health and Ageing, pursuant to subsection 85(2) of the National Health Act 1953, hereby make the following Declaration:
1. This Declaration commences on 1 June 2007.
Declaration No. PB 32 of 2007 under subsection 85(2) of the National Health Act 1953 made on 30 March 2007 with effect from 1 May 2007 is, in this Declaration, referred to as the Principal Declaration.
Schedule 1 to the Principal Declaration is amended:
(a)in respect of the pharmaceutical benefit Glucose Indicator — Blood, by inserting “electrode strips, 50 (Glucoboy),” in column 2, immediately after “electrode strips, 50 (Freestyle Papillon),”;
(b)by inserting, immediately after the details in respect of the pharmaceutical benefit Olanzapine, the following details:
| Column 1 | Column 2 |
| Name of pharmaceutical benefit | Circumstances (if any) specified for the purposes of section 88A of the Act |
| Olmesartan Medoxomil | — |
| Olmesartan Medoxomil with Hydrochlorothiazide | Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan medoxomil monotherapy |
Schedule 3 to the Principal Declaration is amended:
(a) in respect of the pharmaceutical benefit Hydrochlorothiazide, by inserting “Olmesartan Medoxomil with Hydrochlorothiazide” in column 2, immediately after “Irbesartan with Hydrochlorothiazide”;
(b) by inserting, immediately after the details in respect of the pharmaceutical benefit Oestrogens — Conjugated, the following details:
| Column 1 | Column 2 |
| Name of pharmaceutical benefit | Allowable compounds |
| Olmesartan Medoxomil | Olmesartan Medoxomil with Hydrochlorothiazide |
Dated this 26 day of April 2007.
STEPHEN DELLAR
Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
Delegate of the Minister for Health and Ageing
0
0
0